Bookmark and Share
Nitroglycerin (CID 4510) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(23)
 
 
Inactive(7)
 
 
Inconclusive(16)
 
 
Unspecified(61)
 
 
Top Targets:
HNOBA(4)
 
 
NAD binding 8(1)
 
 
Sulfatase(1)
 
 
BioAssay Types:
Literature(97)
 
 
 
 
 
BioActivity Types:
IC50(19)
 
 
 
EC50(13)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 104    Data Row: 107   Total Pages: 3   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103198242]
EC50 0.007In vitro vascular relaxation in canine mesenteric veins precontracted with phenylephrine. [AID218881, Type: Literature]
View
2
[SID103198242]
EC50 0.01In vitro vascular relaxation in canine coronary arteries precontracted with prostaglandin F2alpha. [AID218879, Type: Literature]
View
3
[SID103198242]
IC50 0.016Vasorelaxation activity in the isolated endothelium-denuded rabbit aorta [AID167355, Type: Literature]
View
4
[SID103198242]
EC50 0.022Capacity to increase [Ca2+] entry into the vascular smooth muscle was evaluated on rat aorta strips partially depolarized with 50 mM K [AID175471, Type: Literature]
View
5
[SID103198242]
EC50 0.0224Relaxation of endothelium denucleated strips of rat aorta precontracted with noradrenaline [AID195179, Type: Literature]
View
6
[SID103198242]
EC50 0.027Vasorelaxant activity in pig pulmonary artery by organ bath experiment [AID352262, Type: Literature]
View
7
[SID103198242]
EC50 0.029Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction [AID374757, Type: Literature]
View
8
[SID103198242]
EC50 0.0356Vasodilatory effect in pig pulmonary artery assessed as inhibition of PGF2-alpha-induced contraction [AID309710, Type: Literature]
View
9
[SID103198242]
IC50 0.05888Vasorelaxant activity in endothelium-denuded Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction [AID437027, Type: Literature]
View
10
[SID103198242]
IC50 0.12589Vasorelaxation activity against KCl-induced contraction in isolated Wistar rat thoracic endothelium-denulated aortic rings [AID641620, Type: Literature]
View
11
[SID103198242]
EC50 0.42Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after ALDH2 inhibitor benomyl treatment [AID374758, Type: Literature]
View
12
[SID103198242]
EC50 0.94Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after ALDH2 inhibitor chloral hydrate treatment [AID374759, Type: Literature]
View
13
[SID103198242]
EC50 1.9Effective concentration for relaxation of isolated rat aortic strips, submaximally contracted with phenylephrine at 0.1 uM was determined [AID175666, Type: Literature]
View
14
[SID103198242]
EC50 2.2Compound was tested for its vasodilator effects on endothelium-denuded strips of rat aorta precontracted with noradrenaline [AID175492, Type: Literature]
View
15
[SID103198242]
EC50 4.4Vasodilatory activity in Wistar rat endothelium-denuded cross tolerant thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction preincubated with 0.55 mM GTN for 1 hr followed by washing [AID374756, Type: Literature]
View
16
[SID103198242]
Induction of NO release in Wistar rat liver homogenate at 200 uM by amperometric detection method [AID437026, Type: Literature]
View
17
[SID103198242]
Soluble guanylate cyclase activator [AID742506, Type: other]Guanylate cyclase soluble subunit beta-1 [gi:399328]
View
18
[SID103198242]
Soluble guanylate cyclase activator [AID742506, Type: other]Guanylate cyclase soluble subunit alpha-2 [gi:461897]
View
19
[SID103198242]
Soluble guanylate cyclase activator [AID742506, Type: other]Guanylate cyclase soluble subunit alpha-3 [gi:7404351]
View
20
[SID103198242]
Soluble guanylate cyclase activator [AID742506, Type: other]Guanylate cyclase soluble subunit beta-2 [gi:14916977]
View
21
[SID48414597]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
22
[SID48414597]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results [AID1205, Type: other]
View
23
[SID48414597]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results [AID1208, Type: other]
View
24
[SID103198242]
EC50 100Vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction drug treated 30 mins after 1 uM soluble guanylate cyclase heme site inhibitor ODQ treatment [AID374760, Type: Literature]
View
25
[SID103198242]
Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring in presence of benomyl to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring [AID374762, Type: Literature]
View
26
[SID103198242]
Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring in presence of chloral hydrate to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring [AID374763, Type: Literature]
View
27
[SID103198242]
Ratio of EC50 for vasodilatory activity in Wistar rat endothelium-denuded cross tolerant thoracic aortic ring preincubated with 0.55 mM GTN for 1 hr followed by washing to EC50 for vasodilatory activity in Wistar rat endothelium-denuded thoracic aortic ring [AID374764, Type: Literature]
View
28
[SID103198242]
Cardiac protection in Wistar rat assessed as decrease in infarct size at 5 ug/min/kg for 13 hrs prolonged treatment terminated 3 hrs before ischemia [AID395247, Type: Literature]
View
29
[SID103198242]
Permeability coefficient in human skin [AID311367, Type: Literature]
View
30
[SID103198242]
Anticarcinogenic activity in rat assessed as induction of tumors per day [AID318681, Type: Literature]
View
31
[SID103198242]
Nitric oxide release in PBS at pH 7.4 in 37 degC after 1.5 hrs [AID321898, Type: Literature]
View
32
[SID103198242]
Nitric oxide release in PBS in presence of 5 mM L-cysteine at pH 7.4 in 37 degC after 1.5 hrs [AID321900, Type: Literature]
View
33
[SID103198242]
Nitric oxide release in phosphate buffer containing 5 mM L-cysteine at pH 7.4 incubated at 34 degC after 1.5 hrs [AID352494, Type: Literature]
View
34
[SID103198242]
Nitric oxide release in phosphate buffer at pH 7.4 incubated at 34 degC after 1.5 hrs [AID352500, Type: Literature]
View
35
[SID103198242]
Induction of NO release in phosphate buffer at pH 7.4 [AID457931, Type: Literature]
View
36
[SID103198242]
Induction of NO release in presence of 5 mM L-cysteine [AID457932, Type: Literature]
View
37
[SID103198242]
Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 0.3 mg/kg [AID58416, Type: Literature]
View
38
[SID103198242]
Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 1.0 mg/kg [AID58418, Type: Literature]
View
39
[SID103198242]
Percent change in left ventricle contractile force in anesthetized dogs after intravenous administration at 3.0 mg/kg [AID58420, Type: Literature]
View
40
[SID103198242]
Maximum hypertension was measured in anesthetized dog as percent at the dose of 0.03 mg/kg, i.v. [AID59574, Type: Literature]
View
41
[SID103198242]
Maximum collateral index in anesthetized dog at the dose of 0.03 mg/kg, i.v. [AID59741, Type: Literature]
View
42
[SID103198242]
Collateral index in anesthetized dog at the dose of 0.03 mg/kg, i.v. after 60 minutes of administration [AID60299, Type: Literature]
View
43
[SID103198242]
Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 0.3 mg/kg [AID60813, Type: Literature]
View
44
[SID103198242]
Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 1.0 mg/kg [AID60814, Type: Literature]
View
45
[SID103198242]
Percent change in mean arterial blood pressure after intravenous administration in anesthetized dogs at 3.0 mg/kg [AID60816, Type: Literature]
View
46
[SID103198242]
Percent change heart rate after intravenous administration in anesthetized dogs at 0.3 mg/kg (NC<10%) [AID60819, Type: Literature]
View
47
[SID103198242]
Percent change heart rate after intravenous administration in anesthetized dogs at 1.0 mg/kg [AID60820, Type: Literature]
View
48
[SID103198242]
Percent change in heart rate after intravenous administration in anesthetized dogs at 3.0 mg/kg (NC<10%) [AID60821, Type: Literature]
View
49
[SID103198242]
In vitro NO (nitrous oxide) release by nitrite quanititation using Griess reaction without N-acetyl-cysteamine [AID76451, Type: Literature]
View
50
[SID103198242]
In vitro NO (nitrous oxide) release by nitrite quanititation using Griess reaction in presence of N-acetyl-cysteamine [AID76452, Type: Literature]
View